Himalaya Livline | Vol 6 | No. 5 | Sep–Dec 2023 | 5 Liv.52 DS in the Management of Nonalcoholic Fatty Liver Disease Results It was observed that the NAFLD fibrosis score reduced by the end of month 1 and further reduced by the end of month 2. Similarly, after treatment with Liv.52 DS, there was a reduction in the fibrosis score in patients with indeterminate scores. This indicates that Liv.52 DS helps reduce liver fibrosis associated with NAFLD. Table 1 shows the effect of Liv.52 DS on hepatomegaly; there was a significant improvement after the treatment. After the treatment with Liv.52 DS, the liver size significantly reduced from 17.44 ± 1.9 cm at baseline to 17.29 ± 1.77 cm by the end of month 1 and further reduced to 15.87 cm by the end of month 2 (P < .0001) (Figure). The levels of ALT and AST, which were elevated at baseline, decreased at the end of the study (Table 2). Hematological and biochemical investigation results were within normal limits. No adverse events were reported during the entire study period. The overall compliance with the treatment was good, with no treatment discontinuation. Discussion The hepatoprotective activity observed in this study can be attributed to the synergistic action of the bioactive herbs present in Liv.52 DS—Capparis spinosa, Cichorium intybus, Solanum nigrum, Terminalia arjuna, Cassia occidentalis, Achillea millefolium, and Tamarix gallica. C spinosa prevents elevation of malondialdehyde (plasma and hepatic), AST, and ALT levels. C intybus suppresses the oxidative degradation of DNA in tissue debris. S nigrum protects the DNA against oxidative damage and acts as a Table 1. Effect of Liv.52 DS on Hepatomegaly Liver Size on Ultrasonographic Screening Baseline Month 1 Month 2 Patients, n (%) Patients, n (%) Patients, n (%) > 16 cm (Hepatomegaly) 45 (75) 43 (72) 25 (42) < 16 cm (No Hepatomegaly) 15 (25) 17 (28) 35 (58) Figure. Effect of Liv.52 DS on Liver Size 5 0 10 15 20 25 Liver Size, cm Baseline Month 1 Month 2 Table 2. Effect of Liv.52 DS on LFTs (AST and ALT) Parameter Baseline Month 1 Month 2 AST, IU/L 60.33 ± 13.04 56.43 ± 15.47 54.12 ± 17.26 P < .0339a ALT, IU/L 70.68 ± 18.49 64.13 ± 22.07 P < .0215a 61.9 ± 22.7 P < .0022a Statistical test: ANOVA followed by Tukey’s multiple comparison test. Significance was fixed at P < .05. Values are represented as mean ± SD. aCompared with baseline. ALT, alanine transaminase; AST, aspartate transaminase; LFTs, liver function tests. potent scavenger of hydroxyl and diphenylpicrylhydrazyl radicals. T arjuna reduces cholesterol levels. C occidentalis modulates hepatic enzyme levels. T gallica has a beneficial effect on liver glycogen and serum proteins. Conclusion The findings of the study suggest that Liv.52 DS is safe and effective in the management of NAFLD.
RkJQdWJsaXNoZXIy MjAwNDg=